H.C. Wainwright Reaffirms Their Buy Rating on Evolus (EOLS)

In a report released today, Douglas Tsao from H.C. Wainwright reiterated a Buy rating on Evolus (EOLSResearch Report), with a price target of $15.00. The company’s shares closed yesterday at $7.78.

According to TipRanks, Tsao is a 3-star analyst with an average return of 1.0% and a 37.56% success rate. Tsao covers the Healthcare sector, focusing on stocks such as Apellis Pharmaceuticals, Revance Therapeutics, and Daré Bioscience.

Currently, the analyst consensus on Evolus is a Moderate Buy with an average price target of $15.00.

See Insiders’ Hot Stocks on TipRanks >>

Based on Evolus’ latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $37.16 million and a GAAP net loss of $23.47 million. In comparison, last year the company earned a revenue of $26.1 million and had a GAAP net loss of $15.6 million

Based on the recent corporate insider activity of 29 insiders, corporate insider sentiment is neutral on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Evolus, Inc. is a medical aesthetics company, which engages in the provision of medical aesthetic treatments and procedures. It offers products under the brand of Jeuveau. The company was founded by Scott Cannizzaro in November, 2012 and is headquartered in Newport Beach, CA.

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More